Journal Article

Expression and Prognostic Value of miR-486-5p in Patients with Gastric Adenocarcinoma

Han, Chongxu, Chen, Hui, Ren, Chuanli, Fu, Deyuan, Chen, Yong, Wang, Daxin

2015

Overview

MicroRNA (miR)-486-5p expression is often reduced in human cancers. However, its expression in gastric carcinoma and its relation to clinicopathological features and prognosis are unclear. Tissue microarrays were constructed from 84 patients with gastric adenocarcinoma (GC) who were undergoing radical resection. miR-486-5p expression was detected by miRNA-locked nucleic acid in situ hybridization, and its correlations with clinicopathological features and overall survival were analyzed. Bioinformatic studies predict that fibroblast growth factor 9 (FGF9) is a potential target gene of miR-486-5p. miR-486-5p was mainly located in the cytoplasm of GC cells and neighboring normal tissues. Compared with paracancerous normal tissue, miR-486-5p expression was decreased in 63.1% (53/84) of the GC samples, increased in 32.1% (27/84) and unchanged in 4.8% (4/84). FGF9 expression was decreased in 69.0% (58/84) of GC samples and increased in 31.0% (26/84) compared with normal paracancerous tissues using immunohistochemical analysis. Low or unchanged miR-486-5p expression (P = 0.002), tumor stage (P = 0.001), tumor status (P = 0.001), node status (P = 0.001), tumor size (P = 0.004), and depth of tumor invasion (P = 0.013) were significant negative prognostic predictors for overall survival in patients with GC. After stratification according to American Joint Committee on Cancer (AJCC) stage, low/unchanged miR-486-5p expression remained a significant predictor of poor survival in stage II (P = 0.024) and stage III (P = 0.003). Cox regression analysis identified the following predictors of poor prognosis: tumor status (hazard ratio [HR], 7.19; 95% confidence interval [CI], 1.75-29.6; P = 0.006), stage (HR, 2.62; 95%CI, 1.50-4.59; P = 0.001), lymph node metastasis (HR, 2.52; 95% CI, 1.27-4.99; P = 0.008), low/unchanged miR-486-5p (HR, 2.47; 95% CI, 1.35-4.52; P = 0.003), high level of FGF9 (HR, 2.41; 95% CI, 1.42-4.09; P = 0.001) and tumor size (HR, 2.50; 95% CI, 1.30-4.82; P = 0.006). Low or unchanged expression of miR-486-5p compared with neighboring normal tissues was associated with a poor prognosis, while high expression was associated with a good prognosis in GC. miR-486-5p may thus be useful for evaluating prognosis and may provide a novel target treatment in patients with GC.

• Publisher: Public Library of Science,Public Library of Science (PLoS)
• Subject: Adenocarcinoma / Adenocarcinoma - genetics / Adenocarcinoma - mortality / Adenocarcinoma - pathology / Adult / Aged / Analysis / Brain cancer / Breast cancer / Care and treatment / Cell cycle / Chromosome 5 / Confidence intervals / Cytoplasm / DNA microarrays / Female / Fibroblast growth factor 9 / Fibroblast Growth Factor 9 - genetics / Fibroblast Growth Factor 9 - metabolism / Fibroblast growth factor receptor 9 / Fibroblast growth factors / Fibroblasts / Follow-Up Studies / Gastric cancer / Gene Expression / Growth factors / Hospitals / Humans / Hybridization / Immunohistochemistry / In Situ Hybridization / Kinases / Lung cancer / Lymph nodes / Lymphatic system / Male / Medical prognosis / Metastases / Metastasis / MicroRNA / MicroRNAs / MicroRNAs - genetics / Middle Aged / miRNA / Neoplasm Metastasis / Neoplasm Staging / Nucleic acids / Patients / Prognosis / Prostate cancer / Regression analysis / Ribonucleic acid / RNA / RNA Interference / RNA, Messenger - genetics / Statistical analysis / Stem cells / Stomach cancer / Stomach Neoplasms - genetics / Stomach Neoplasms - mortality / Stomach Neoplasms - pathology / Survival / Survival Analysis / Tissues / Tumor Burden / Tumors